secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organogenesis Holdings Inc. (ORGO)
CIK:        0001661181
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-076595
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organogenesis reports record Q4 2025 revenue $225M; FY2026 guidance implies 25-38% decline
--------------------------------------------------------------------------------

- Q4 2025 net product revenue $225.1M (+78% YoY); Advanced Wound Care $217.2M (+83% YoY).
- Q4 net income $43.7M ($0.25/sh) vs $7.7M ($0.04/sh) a year ago; Adj. EBITDA $84.2M.
- FY2025 net product revenue $563.0M (+17% YoY); net income $37.0M vs $0.9M in FY2024.
- FY2026 total net revenue guidance $350M - $420M, a 25% to 38% decline from FY2025; expects Q1 drop then sequential growth.
- Cash and equivalents $94.3M with no outstanding debt as of Dec 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661181/000119312526076595/0001193125-26-076595-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661181/000119312526076595/orgo-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-076595

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer